One Of Two Pfizer Lipitor Patents Upheld By U.K. Court
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says the British court’s ruling, which could keep Ranbaxy’s generic off the market until 2011, “has no bearing” on atorvastatin patent litigation in the U.S.
You may also be interested in...
Lipitor’s U.K. Exclusivity Affirmed In Appellate Decision
Ranbaxy’s generic atorvastatin may not launch in the U.K. until November 2011, Pfizer says.
Lipitor’s U.K. Exclusivity Affirmed In Appellate Decision
Ranbaxy’s generic atorvastatin may not launch in the U.K. until November 2011, Pfizer says.
PTO Reconsidering Validity Of One Of Pfizer’s Lipitor Patents
Patent & Trademark Office will re-examine whether claims covering the crystalline form of atorvastatin were disclosed in the prior art. The patent runs until January 2017 and is the latest expiring of five Lipitor patents listed in the “Orange Book.”